

Tianhong Li, M.D., Ph.D.

Clinical Interests
Dr. Li has been involved in several translational research projects since her fellowship training, leading to the publication of several original research papers. Areas of her current studies are in optimizing anti-epidermal growth receptor (EGFR) therapy in non-small cell lung cancer and combining charge farnesyl transferase inhibitor tipifarnib with cytotoxic and hormonal agents in breast cancer. She has served as principle investigator of several investigator-initiated studies in breast cancer and lung cancer.
As a physician-scientist, her main research focus is on understanding the mechanisms of action of novel targeted agents and developing rational therapeutic strategies for breast and lung cancer.

Title
Assistant Professor
Co-Director, Phase I Program

Specialty
Cancer, Hematology and Oncology, Internal Medicine

Department
Internal Medicine

Division
Hematology and Oncology

Center/Program Affiliation
UC Davis Comprehensive Cancer Center

Address/Phone
UC Davis Comprehensive Cancer Center, 4501 X St. Sacramento, CA 95817
Phone: 800-362-5566

Additional Phone
Physician Referrals: 800-362-5566

Education
M.D., Beijing University School of Medicine, Beijing, 1989
Ph.D., Loyola University, Stritch School of Medicine, Maywood , Illinois, 1996

Internships
Beth Israel Medical Center, Albert Einstein College of Medicine, New York, NY, 1997-1998

Residency
Beth Israel Medical Center, Albert Einstein College of Medicine, New York, NY, 1998-2000

Fellowships
Montefiore Medical Center, Albert Einstein College or Medicine, Bronx, NY, 2003

Board Certifications
American Board of Internal Medicine, 2000
American Board of Internal Medicine, Hematology and Oncology, 2003

Professional Memberships
American Association of Cancer Research
American Society of Clinical Oncology

UCDAVIS
HEALTH SYSTEM



Tianhong Li, M.D., Ph.D.

American Society of Hematology
Breast Evaluation Center, Montefiore Medical Center/Albert Eintstein Cancer Center
Chinese American Hematologist/Oncologist Network
Eastern Cooperative Oncology Group
Experimental Therapeutic Program at the UC Davis Cancer Center
International Association for the Study of Lung Cancer
NCI/Cancer Therapy Evaluation Program

Honors and Awards

Mentor for Third Prize, 2008 Annual Young Investigator Award, Montefiore Medical Center, Bronx, NY, 2008

Third Prize, Eleventh Annual Young Investigator Award, Montefiore Medical Center, Bronx, NY, 2007

Third Prize, Ninth Annual Young Investigators Symposium, Montefiore Medical Center, Bronx, NY, 2005

Fellowship, Second Accelerating Anticancer Agent Development and Validation Workshop, Sponsored by: Duke Comprehensive Cancer Center, American Association for Cancer Research, American Society of Clinical Oncology, National Cancer Institute, NIH, and U.S. Food and Drug Administration (FDA), North Bethesda, Maryland, 2005

Fellowship, Second National Medical Oncology Fellows' Forum, 2003

Fellowship, Fifty FECS (Federation of European Cancer Societies)-AACR (American Association for Cancer Research)-ASCO (American Society of Clinical Oncology) Workshop on "Methods in Clinical Cancer Research", Flims, Switzerland, 2003

Fellowship, First NCI-Sponsored OncoTalk Retreat (Teaching Communication Skills with Patients to Medical Oncology Fellows), Aspen, Colorado, 2002

ECOG-Aventis Young Investigator, ECOG Annual Meeting, 2002

Graduated top 5% of class (a size of over 200 students), Beijing Medical University, 1989

Award for Outstanding Research Accomplishment, Beijing Medical University, 1988

Select Recent Publications

Pohl, N.M., Tong, C., Fang, W., Bi, X., Li, T., and Yang, W. Transcriptional Regulation and Biological Functions of Selenium-Binding Protein 1 in Colorectal Cancer *in vitro* and in Nude Mouse Xenografts. *PLoS ONE*, 4(11): e7774. doi:10.1371/journal.pone.0007774.

Ling, Y.-H., Li, T., Perez-Soler, R, and Haigentz, Jr., M. Glycosylation inhibitor Tunicamycin enhances the cytotoxicity of Erlotinib in human non-small cell lung cancer cells. *Cancer Chemother Pharmacol*, 2009 Aug; 64(3):539-48. Epub 2009 Jan 8.

Li, T., Paul J. Christos, Joseph A Sparano, Dawn L. Hershman, Katie O'Brien, Shira Hoschander,



Tianhong Li, M.D., Ph.D.

John J. Wright, and Linda T. Vahdat. Phase II study of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in postmenopausal patients with hormone receptor-positive breast cancer: New York Cancer Consortium Trial P6205. *Ann Oncol*, 2009 Apr; 20(4):642-7. Epub 2009 Jan 19.

Li, T., Ho, L., Piperdi, B., Macapinlac, M., Rigas, J., Camacho, F., Perez-Soler, R, Gucalp, R. Phase II study to evaluate the efficacy and safety of bortezomib (PS-341) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC). *Lung Cancer*, 2009 Jun 11. [Epub ahead of print].

Li, T., Lara, P.N., Mack, P.C., Perez-Soler, R, and Gandara, D.R Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer. *Current Drug Targets*, January 2010 (in press). 2009 Sep 19. [Epub ahead of print] PMID: 19839922.

Sparano, J.A, Moulder, S., Kazi, A, Coppola, D., Negassa, A, Vahdat, L., Li, T., Pellegrino, C., Fineberg, S., Munster, P., Malafa, M., David Lee, D., Hoschander, S., Hopkins, U., Hershman, D. Wright, J.J., Kleer, C., Merajver, S., and Sebti, S., M. Phase II trial of the farnesyl transferase inhibitor tipifarnib plus neoadjuvant dose-dense doxorubicin-cyclophosphamide in patients with locally advanced breast cancer. *Clin Cancer Res*, 2009 Apr 15; 15(8):2942-8. Epub 2009 Apr 7.

D.R Gandara, D.R., Mack, P.C., Li, T., Lara, P.N., and Herbst, R Evolving Treatment Algorithms for Advanced Non-Small Cell Lung Cancer: 2009 looking toward 2012. *Clinical Lung Cancer*, 2009 Nov; 10(6):392-4.

Li, T. and Perez-Soler, R. Cutaneous toxicity with EGFR inhibitors. *Target Oncol*, 2009 Apr; 4(2): 107-19.

Li, T. and Sparano, J.A Farnesyl transferase inhibitors. *Cancer Invest*, 2008 Aug; 26(7):653-61.

Li, T. and Sparano, J.A. Farnesyl transferase inhibitors. Cancer Invest. 2008 Aug; 26(7):653-61.

Li, T., Ling, Y.-H., and Perez-Soler, R Tumor dependence on the EGFR signaling pathway expressed by the p-EGFRp-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene. *J Thorac Oncol*, 2008 Jun; 3(6):643-7.

Li, T., Ling, Y.-H., and Perez-Soler, R. Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene. J Thorac Oncol, 2008 Jun;3(6):643-7.

Wang, S.T., Jin, K.L., and Li, T.H. The inhibitory effect of Deferoxamine on DNA synthesis of human lymphocytes. Chin Med J (Engl), 102 (12): 902-5, 1989.

© 2013 UC Regents

UCDAVIS
HEALTH SYSTEM